ClinicalTrials.gg
CompletedNCT07333963Updated Oct 28, 2026

Adjunctive Kinesiotaping in Surgical Treatment of Impacted Mandibular Third Molars

An interventional study of Kinesiotaping and extraction of impacted third lower molar in Impacted Third Molar Tooth, sponsored by Medical University of Silesia. Completed at 1 site in Poland. Open to participants aged 16 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Sep 2023, registered Dec 2025).
Updated Oct 28, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
16 Years to 64 Years
Sex
All
01

Study summary

PATIENT INFORMATION SHEET Participants are invited to take part in a clinical study involving surgical removal of an impacted lower wisdom tooth. Participation in this study is entirely voluntary.

The purpose of this study is to observe the healing process after wisdom tooth removal and to assess whether the use of elastic therapeutic tape placed on the skin (kinesiotaping) may support recovery.

SURGICAL PROCEDURE The procedure will be performed under local anesthesia and will include: - Administration of local anesthesia

  • Incision of the gum
  • Exposure of the impacted tooth and surrounding bone
  • Removal of the tooth
  • Cleaning of the surgical site - Placement of sutures After the surgery, standard post■operative instructions will be provided. STUDY PROCEDURE

After the surgical procedure, patients will be randomly assigned to one of two groups:

  1. Standard post■operative care
  2. Post■operative care combined with application of elastic therapeutic tape on the skin of the face and neck area If the participants are assigned to the tape group, the tape will be applied immediately after surgery by qualified medical personnel and will remain in place for several days.

FOLLOW■UP VISITS Participant will be asked to attend follow■up visits on specific days after the procedure to allow the medical team to assess healing. PAIN MANAGEMENT Participant will be allowed to take pain medication if necessary, following medical advice.

VOLUNTARY PARTICIPATION Participation in this study is voluntary. Participant may withdraw from the study at any time without giving a reason and without affecting participants medical care.

CONFIDENTIALITY All medical information collected during the study will be handled confidentially and used solely for research purposes.

02

Conditions studied

  • Impacted Third Molar Tooth

Browse trials for

Keywords

  • kinesiotaping, impacted teeth
03

In context

Tooth, Impacted

122 studies on the registry are indexed under Tooth, Impacted; 15 are open to participants now.

This study's enrollment of 62 is below the median of 70 across 88 interventional studies indexed under Tooth, Impacted.

Browse Tooth, Impacted studies →

Lead sponsor

Medical University of Silesia is the lead sponsor of 115 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No systemic diseases (generally healthy patient)

Indication for surgical extraction of impacted lower third molars for:

orthodontic reasons

surgical reasons

prophylactic reasons

Age between 16 and 64 years

Written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Presence of chronic systemic diseases, including:

diabetes mellitus

hypertension

diseases

Pharmacological treatment in the period preceding the surgery

Pregnancy

Substance abuse or dependence

Head and neck

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Research group

    Group undergoing Kinesiotaping after the surgical procedure

    Other: Kinesiotaping · Procedure: extraction of impacted third lower molar

  • Other
    Control Group

    no kinesiotaping

    Procedure: extraction of impacted third lower molar

Interventions

  • OtherKinesiotaping

    basic lymphatic KT application

  • Procedureextraction of impacted third lower molar

    basic surgical extraction

06

What researchers measure

Primary outcomes

  1. postoperative pain intensity

    Postoperative pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity.

    Time frame: 2 days post-surgery and 7 days post-surgery

  2. Maximum Mouth Opening (MMO)

    Maximum mouth opening will be measured using a caliper as the interincisal distance between the upper and lower incisors at maximum mouth opening.

    Time frame: FinishBefore surgery, 2 days after surgery, and 7 days after surgery

  3. Facial Soft Tissue Swelling

    Facial swelling will be assessed using linear tape measurements between six predefined facial reference points. The sum of distances will be used for analysis.

    Time frame: Before surgery, 2 days after surgery, and 7 days after surgery

  4. Postoperative Analgesic Consumption

    The total number of ketoprofen 100 mg tablets taken by each participant will be recorded as a measure of postoperative analgesic demand.

    Time frame: Day of surgery, 2 days after surgery, and 7 days after surgery

07

Study locations

1 site
  • Uniwersyteckie centrum stomatologii
    Bytom, Silesian Voivodeship 41-902, Poland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Sep 2025, 23 months.

Of 55 non-industry interventional studies with no phase under Tooth, Impacted, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 35. This study's 23 months is above that.

Counting every sponsor, half of 56 studies reached it within 20 months; a quarter within 8 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start May 2023 → Sep 2023, primary completion Dec 2025 → Sep 2025 and completion Dec 2025 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Jan 12, 2026
StartActual
Sep 13, 2023was May 2023
Primary completionActual
Sep 1, 2025was Dec 2025
CompletionActual
Sep 1, 2025was Dec 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 14, 2023→Sep 13, 2023
Oct 28, 2026
Primary completion
Dec 2, 2025→Sep 1, 2025
Oct 28, 2026
Study completion
Dec 8, 2025→Sep 1, 2025
Oct 28, 2026
Enrollment
70→62
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date May 14, 2023→Sep 13, 2023
    Primary completion Dec 2, 2025→Sep 1, 2025
    Study completion Dec 8, 2025→Sep 1, 2025
    Enrollment 70→62

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07333963
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Sep 13, 2023
Primary completion
Sep 1, 2025
Completion
Sep 1, 2025
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion